Dexmedetomidine Supplemented Intravenous Analgesia in Elderly After Orthopedic Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

712

Participants

Timeline

Start Date

October 28, 2018

Primary Completion Date

December 6, 2019

Study Completion Date

December 6, 2022

Conditions
ElderlyOrthopedic SurgeryAnalgesiaDexmedetomidinePostoperative DeliriumLong-term Outcome
Interventions
DRUG

Dexmedetomidine

Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and sufentanil (1.25 ug/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.

DRUG

Placebo

Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of placebo and sufentanil (1.25 ug/m), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.

Trial Locations (2)

100034

Peking University First Hospital, Beijing

102208

Beijing Jishuitan Hospital, Beijing

All Listed Sponsors
collaborator

Beijing Jishuitan Hospital

OTHER

lead

Peking University First Hospital

OTHER

NCT03629262 - Dexmedetomidine Supplemented Intravenous Analgesia in Elderly After Orthopedic Surgery | Biotech Hunter | Biotech Hunter